- 14T-MC-JVBA - Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab vs. Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Platinum-Based Therapy. Accrual limited to Abington Cancer Care Specialists.
Rationale: The investigational drug used in this study may stop the growth of tumor cells by blocking its supply of nutrients and oxygen. It can be combined with chemotherapy drugs, which work in different ways to stop the growth of tumor cells. It is not yet known whether the investigational agent used in this study when given in combination with chemotherapy is more effective than chemotherapy alone for the treatment of non-small cell lung cancer (NSCLC). Purpose: The purpose of this study is to determine whether this investigational drug can help lung cancer patients live longer when it is given with chemotherapy treatment (docetaxel or taxotere). The study will include only patients who have already been treated with chemotherapy but who have progressed, either while being treated, or after completion of treatment. The study will also include genetic testing, which will help researchers to better understand which patients might benefit from this investigational drug in the future. (NCT01168973)
- ECOG E1508 - Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patinets with Extensive Stage Small Cell Lung Cancer.
Drugs used in chemotherapy, such as cisplatin and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. GDC-0449 may slow the growth of tumor cells. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving cisplatin and etoposide are more effective when given together with GDC-0449 or cixutumumab in treating small cell lung cancer. This randomized phase II trial is studying cisplatin and etoposide phosphate to see how well they work when given with or without GDC-0449 or cixutumumab in treating patients with extensive-stage small cell lung cancer. (NCT00887159)
- ECOG E5597 - Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage 1 Non-Small Cell Lung Cancer.
Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer. (NCT00008385)
- PrECOG - PrE0501 - A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination with Docetaxel and Carboplatin +/- Placebo or Maintenance Therapy with Vandetanib in Patients with IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC). Accrual limited to Abington Cancer Care Specialists.
It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor are formed through a process called angiogenesis. Vandetanib is an investigational drug that acts by producing what is called an anti-angiogenic effect. An Anti-angiogenic effect is able to inhibit the development of new blood vessels required by tumors to survive by blocking the growth factors needed to form new blood vessels. The purpose of this study is to determine if the addition of vandetanib to a standard chemotherapy regimen will slow or stop the growth of the cancer for a longer period of time compared to the time period generally gained from the use of standard chemotherapy alone. (NCT00697297) (Trial info provided by PrECOG, LLC.)
- RTOG 0915 - A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.
Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which regimen of stereotactic body radiation therapy is more effective in treating patients with non-small cell lung cancer. This randomized phase II trial is studying the side effects of two radiation therapy regimens and to see how well they work in treating patients with stage I non-small cell lung cancer. (NCT00960999)